CELGENE

Tweet this page
<
2012
2013
2014
2015
2016
2017
2018
2019
>
No longer registered - Registration as it was on 25 Mar 2019
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

550,000€

Financial year: Jan 2018 - Dec 2018

Lobbyists (Full time equivalent)

2.25 Fte (5)

Lobbyists with EP accreditation

10

High-level Commission meetings

6

Lobbying Costs over the years

  • Info

    CELGENE

    EU Transparency Register

    37955905654-37 First registered on 14 Apr 2011

    Goals / Remit

    Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

    Main EU files targeted

    Celgene works with European institutions to raise awareness of diseases with a high unmet medical need - such as rare diseases, rare cancers and immune and inflammatory diseases - to drive greater focus on patients with these underserved conditions. We seek cooperation in policy developments that improve regulatory processes for pharmaceuticals and ensure the right environment for research and industry in Europe. We foster debates around improved and equal access to innovative medicines for patients through open dialogues with European policy-makers.

    We therefore monitor EU initiatives related to the registration and evaluation of medicines as well as the current EU policy debates on innovation in healthcare, Health Technology Assessment cooperation, access to medicines and intellectual property.

    Address

    Head Office
    Morris Avenue, 86
    Summit NJ07901
    UNITED STATES
    EU Office
    Rue du Trône, 108
    Bruxelles 1050
    BELGIUM
  • People

    Total lobbyists declared

    5

    Employment timeLobbyists
    75%1
    50%2
    25%2

    Lobbyists (Full time equivalent)

    2.25

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    10 accreditations were / are live (in bold) for the selected state of 29 Nov 2022

    Name Start date End Date
    Ms Esther BERDEN 21 Feb 2020 28 Feb 2021
    Mr Erwan Gicquel 16 Jan 2020 15 Jan 2021
    Mr Emmanuel Chantelot 18 Dec 2019 17 Dec 2020
    Mr Silviu Popa 17 Oct 2019 16 Oct 2020
    Ms Cassandre Sergent 20 Sep 2019 18 Sep 2020
    Ms Esther BERDEN 19 Feb 2019 18 Feb 2020
    Mr Erwan Gicquel 22 Jan 2019 21 Jan 2020
    Mr Emmanuel Chantelot 22 Jan 2019 21 Jan 2020
    Ms Cassandre Sergent 01 Sep 2018 30 Aug 2019
    Mr Silviu Popa 14 Jun 2018 13 Jun 2019
    Mr Adam PARNABY 31 Jan 2018 30 Jan 2019
    Mr Erwan Gicquel 08 Dec 2017 06 Dec 2018
    Mr Emmanuel Chantelot 28 Nov 2017 27 Nov 2018
    Ms Cassandre Sergent 31 Aug 2017 24 Aug 2018
    Mr Silviu Popa 20 Jul 2017 21 Jun 2018
    Mr Erwan Gicquel 16 Dec 2016 15 Dec 2017
    Mr Emmanuel Chantelot 01 Nov 2016 31 Oct 2017
    Ms Cassandre Sergent 30 Aug 2016 26 Aug 2017
    Ms Laura GUTIERREZ 19 Jul 2016 01 Jul 2017
    Mr Silviu Popa 19 Jul 2016 01 Jul 2017
    Ms Lugdivine Le Dez 19 Jul 2016 01 Jul 2017
    Mr Christoph GLIESING 10 Oct 2015 08 Oct 2016
    Ms Laura GUTIERREZ 05 Jun 2015 03 Jun 2016
    Mr Silviu Popa 05 Jun 2015 03 Jun 2016
    Ms Caroline Correas 14 Nov 2014 12 Nov 2015
    Ms Lugdivine Le Dez 14 Nov 2014 12 Nov 2015
    Ms Laura GUTIERREZ 29 Jul 2014 25 Jul 2015
    Serge De Ruysscher 26 Jun 2014 24 Jun 2015
    Mr Silviu Popa 14 Jun 2014 12 Jun 2015
    Ms Lugdivine Le Dez 28 Nov 2013 26 Nov 2014
    Ms Caroline Correas 01 Nov 2013 30 Oct 2014
    Mr Julien Patris 21 Aug 2013 14 Aug 2014
    Ms Laura GUTIERREZ 30 Jul 2013 26 Jul 2014
    Mrs Cassandra Elsa Birgitta JULIN 11 Jan 2013 29 Mar 2013
    Mrs Cassandra Elsa Birgitta JULIN 06 Feb 2012 31 Oct 2012
    Mrs Laura GUTIERREZ 06 Feb 2012 31 Jul 2012
    Mr Julien Claude PATRIS 24 Jan 2012 31 Dec 2012

    Complementary Information

    While several Celgene employees contribute to the company’s activities falling under the scope of the Transparency Register, only 5 Celgene employees spend more than 10% of their respective work time on this.

    Person in charge of EU relations

    Mr Emmanuel Chantelot (Executive Director, Government Relations and Policy, Worldwide Markets)

    Person with legal responsibility

    Mr Mark Alles (Chairman and Chief Executive Officer)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    Celgene is a member of following organizations in Brussels:
    European Federation of Pharmaceutical Industries and Associations (EFPIA)
    European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
    American Chamber of Commerce to the European Union (AmCham EU)
    Friends of Europe
    European Policy Centre

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2018 - Dec 2018

    Lobbying costs for closed financial year

    550,000€

    Other financial info

    The estimated costs of Celgene arising from activities for the year 2018 covered by the Register include staff costs based on the full-time equivalents already declared, payment to third parties (e.g. fees for consultants) and membership and related fees for joining relevant networks and structures (e.g. trade associations).
    This new estimate follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    None

    Other activities

    None declared

  • Meetings

    Meetings

    6 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

    • Date 30 Nov 2017 Location Brussels
      Subject Investment, innovation and IP protection
      Cabinet Cabinet of Vice-President Jyrki Katainen
      Portfolio Jobs, Growth, Investment and Competitiveness
      Commission
      • Jyrki Katainen (Vice-President)
    • Date 29 Nov 2017 Location Brussels
      Subject Pharmaceutical incentives, antimicrobial resistance
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Commission
      • Annika Nowak (Cabinet member)
      • Vytenis Andriukaitis (Commissioner)
      Other Lobbyists
    • Date 27 Nov 2015 Location Brussels
      Subject Biopharmaceutical industry's contribution to jobs and growth
      Cabinet Cabinet of Vice-President Jyrki Katainen
      Portfolio Jobs, Growth, Investment and Competitiveness
      Commission
      • Grzegorz Radziejewski (Cabinet member)
      Other Lobbyists
    • Date 27 Apr 2015 Location Brussels, Belgium
      Subject Biopharmaceutical industry
      Cabinet Cabinet of Commissioner Elżbieta Bieńkowska
      Portfolio Internal Market, Industry, Entrepreneurship and SMEs
      Commission
      • Kaius Kristian Hedberg (Cabinet member)
      • Rolf Carsten Bermig (Cabinet member)
    • Date 04 Feb 2015 Location Brussels
      Subject Access to innovative medicine
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Commission
      • Annika Nowak (Cabinet member)
      Other Lobbyists
    • Date 04 Feb 2015 Location Brussels
      Subject Janssen EMEA
      Cabinet Cabinet of Vice-President Jyrki Katainen
      Portfolio Jobs, Growth, Investment and Competitiveness
      Commission
      • Aura Salla (Cabinet member)
Download this datacard